Ascletis Pharma Inc.
ASCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $6 | $2 | $1 | $1 |
| - Cash | $2 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -15.7% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 11.2% | 57.3% | – | -125.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -16,991.3% | -17,501% | – | -2,196.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8,136.1% | -13,298.4% | – | -1,270.1% |
| EPS Diluted | -0.091 | -0.173 | -0.128 | -0.121 |
| % Growth | 47.2% | -34.9% | -6.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |